Signals, Powered By EquityPandit
The USFDA has completed inspection of Divis Laboratories unit-I at Choutuppal, Telangana with no 483 observations.
The inspection was a general cGMP inspection by the FDA and was conducted by USFDA from May 14-16 , and has been completed with zero 483 observations.
Further, the company’s board of directors are scheduled to meet on May 26, 2018, to consider and approve standalone and consolidated audited financial results for the year ended March 31, 2018 and to recommend dividend, if any, on equity shares for the financial year 2017-18.
